Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menopause Hot Flashes Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women

NCT01126801
View directory record Official record
Conditions
Menopausal Depression
Interventions
Estradiol, Placebo control
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mindfulness Based Stress Reduction for Hot Flashes

NCT00317304
View directory record Official record
Conditions
Hot Flashes, Stress
Interventions
Mindfulness-based stress reduction
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women

NCT07238478
View directory record Official record
Conditions
Joint Discomfort, Joint Pain, Stiffness, Function, Joint Pain, Hot Flashes, Hot Flash, Night Sweats, Vasomotor Symptoms
Interventions
JDS-HF3.0, Placebo
Dietary Supplement · Other
Lead sponsor
Bonafide Health
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Study of MF101 in Postmenopausal Women

NCT00906308
View directory record Official record
Conditions
Hot Flushes, Vasomotor Symptoms
Interventions
MF101 5 g/day, Placebo, MF101 10 g/day
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Group Therapy for the Management of Menopause Symptoms in Mood Disorders

NCT02860910
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Menopause
Interventions
Cognitive Behavioral Group Therapy
Behavioral
Lead sponsor
Danette Conklin, PhD
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

NCT07218445
View directory record Official record
Conditions
Obesity, Menopause Hot Flashes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause

NCT05030584
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
36
States / cities
Mobile, Alabama • Mesa, Arizona • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

NCT04003389
View directory record Official record
Conditions
Hot Flashes
Interventions
fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
142
States / cities
Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 108 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes

NCT00272935
View directory record Official record
Conditions
Hot Flashes
Interventions
Cenestin 0.3 mg Tablets, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Huntsville, Alabama • Montgomery, Alabama • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

NCT01080300
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended Release, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause

NCT00314964
View directory record Official record
Conditions
Hot Flashes
Interventions
PD-0299685
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Phytoserms for Menopause Symptoms and Age-Associated Memory Decline

NCT01723917
View directory record Official record
Conditions
Hot Flashes, Memory Loss
Interventions
PhytoSERM tablet, placebo
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

NCT05099159
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Womens Study to Alleviate Vasomotor Symptoms

NCT04587154
View directory record Official record
Conditions
Hot Flashes
Interventions
low-fat vegan diet with 1/2 cup soybeans daily
Other
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Reducing the Experience of Menopausal Symptoms Through Temperature

NCT03937466
View directory record Official record
Conditions
Hot Flashes, Menopause
Interventions
Cooling mattress pad
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

NCT00026286
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Menopausal Symptoms
Interventions
conjugated estrogens, medroxyprogesterone
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

NCT07042516
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Asimadoline
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
40 Years to 62 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

NCT03596762
View directory record Official record
Conditions
Menopause, Hot Flashes, Night Waking
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Mesa, Arizona • San Diego, California • Aventura, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Yoga on Objective and Subjective Menopausal Hot Flashes

NCT01073397
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Yoga
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
45 Years to 58 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial

NCT00666913
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
informational intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TU 025 Keishi Bukuryo Gan for Post-menopausal Hot Flash Management

NCT00119418
View directory record Official record
Conditions
Hot Flashes, Menopause
Interventions
TU 025 Keishi Bukuryo Gan
Drug
Lead sponsor
Plotnikoff, Gregory A., M.D.
Individual
Eligibility
45 Years to 58 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2010 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

NCT04090957
View directory record Official record
Conditions
Vasomotor Symptoms, Menopausal Symptoms
Interventions
Estetrol oral tablet, Placebo oral tablet
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,015 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
111
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Cepham Supplement on Hot Flashes and Menopausal Symptoms in Postmenopausal Women

NCT06939868
View directory record Official record
Conditions
D008593
Interventions
Shatavari Root Extract, oral capsule
Dietary Supplement
Lead sponsor
Jacksonville University
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

NCT05042362
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
55
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 17, 2026, 4:09 AM EDT